<unk>  is a substrate for CYP2D6. Concurrent treatment with a CYP2D6 inhibitor such as bupropion, fluoxetine, or paroxetine has been shown to increase plasma<unk>  by 100% or more, as well as increase N-desmethylatomoxetine levels and decrease plasma 4-hydroxyatomoxetine levels by a similar degree.<unk>  has been found to directly inhibit hERG potassium currents with an IC50 of 6.3 μM, which has the potential to cause arrhythmia. QT prolongation has been reported with<unk>  at therapeutic doses and in overdose; it is suggested that<unk>  not be used with other medications that may prolong the QT interval, concomitantly with CYP2D6 inhibitors, and caution to be used in poor metabolizers. Other notable drug interactions include: * Antihypertensive agents, due to<unk>  acting as an indirect sympathomimetic * Indirect-acting sympathomimetics, such as pseudoephedrine, norepinephrine reuptake inhibitors, or MAOIs * Direct-acting sympathomimetics, such as phenylephrine or other α1 adrenoceptor agonists, including pressors such as dobutamine or isoprenaline and β2 adrenoceptor agonists * Highly plasma protein-bound drugs:<unk>  has the potential to displace these drugs from plasma proteins which may potentiate their adverse or toxic effects. In vitro,<unk>  does not affect the plasma protein binding of aspirin, desipramine, diazepam, paroxetine, phenytoin, or warfarin
Atomoxetine
Guanfacine
Dapoxetine
Vortioxetine
Edivoxetine
Duloxetine
Fluoxetine
Fluparoxan